Exelixis Options Cheap After Cancer Drug Scores Key FDA Win

EXEL's Cabometyx has been approved for expanded usage

Dec 20, 2017 at 9:26 AM
facebook twitter linkedin

The U.S. Food and Drug Administration (FDA) yesterday expanded the use of Exelixis, Inc.'s (NASDAQ:EXEL) drug, Cabometyx, to treat those with advanced kidney cancer. The decision comes well ahead of the FDA's mid-February action date, and earned EXEL stock a price-target hike to $38 from $35 at SunTrust Robinson. RBC, meanwhile, projected a $1 billion market opportunity for the biotech.

In reaction, EXEL shares are trading up 4.5% ahead of the bell. The stock's had a standout year, up 78.9% so far in 2017 based on last night's close at $26.68. The security's momentum has stalled since a mid-October bull gap -- sparked by positive Cabometyx data -- but has found a firm foothold atop its 140-day moving average, which contained a late-September retreat, as well.

A capitulation from short sellers could certainly keep this rally going. As of the Dec. 1 reporting period, 18.59 million EXEL shares were sold short -- representing more than nine days' worth of pent-up buying demand, at the stock's average pace of trading.

And while relatively few options traders have targeted the drug stock -- total open interest of 109,856 contracts ranks in the 27th annual percentile -- it's an attractive time to buy premium on Exelixis. While EXEL's Schaeffer's Volatility Index (SVI) of 45% ranks in the 4th percentile of its annual range, the equity's 30-day at-the-money implied volatility of 45.3% ranks below 95% of comparable readings taken in the past year. These two volatility indicators suggest low expectations are being priced into short-term contracts.



Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!